Driveline-related infections after left ventricular assist device implantation: A single center experience

Öz

Aim: The most common complication after left ventricular assist device implantation is driveline-induced infections. This complication severely deteriorates quality of life of the patients. The aim of this study was to investigate driveline infections in patients with left ventricular assist device and to introduce our treatment strategy.

Material and Methods: Between May 2013 and October 2018, 90 adult patients who underwent left ventricular assist device implantation were included. Driveline infection rates, characteristics, pathogen microorganisms were investigated. Treatment options for infections were also analyzed.

Results: The mean age of the patients was 46.3 ± 13.7 and 83.3% (75/90) were male. Dilated cardiomyopathy was present in 62.2% of the patients. Driveline infection was detected in 35.5% (32/90) of the patients. The mean time between implantation and driveline infection was 304 ± 309 (15-1500) days. The most commonly detected microorganisms from swabs and/or tissue cultures were gram positive cocci. Seven patients required oral antibiotic treatment whereas 25 patients required systemic antibiotic treatment. While infection was controlled by oral/systemic antibiotic therapy in 13 patients, 15 patients underwent surgical debridement, three patients required translocation and heart transplant was required in one patient. None of the patients had uncontrolled infection requiring device extraction.

Conclusion: Left ventricular assist device implantation carries high risk of driveline infection; In this study, the rate was found to be 24.4% in the first year. Infection was controlled by oral or systemic antibiotic therapy and/or debridement therapy in selected cases, driveline translocation and heart transplant were rarely required.

Anahtar Kelimeler

• Left ventricular assist device,driveline infection,exit site.

Sol ventrikül destek cihazı implantasyonu sonrası driveline ile ilişkili enfeksiyonlar: Tek merkez deneyimi

Öz

Amaç: Sol ventrikül destek cihazı sonrası görülen en sık komplikasyon driveline kaynaklı enfeksiyonlardır. Bu komplikasyon hastaların hayat kalitesini ileri derecede bozmaktadır. Bu çalışmanın amacı sol ventrikül destek cihazı takılan hastalarda driveline enfeksiyonlarını araştırmak ve tedavi stratejimizi ortaya koymaktır.

Gereç ve Yöntemler: Mayıs 2013 ile Ekim 2018 tarihleri arasında sol ventrikül destek cihazı takılan 90 erişkin hasta çalışmaya dahil edildi. Driveline enfeksiyon oranları, özellikleri, patojen mikroorganizmalar araştırıldı. Ayrıca enfeksiyonlara karşı uygulanan tedavi seçenekleri incelendi.

Bulgular: Hastaların ortalama yaşları 46,3 ± 13,7 idi ve %83,3’ ü (75/90) erkekti. Hastaların %62,2’ sinde dilate kardiyomiyopati mevcuttu. Tüm hastaların %35,5’inde (32/90) driveline enfeksiyonu tespit edildi. İmplantasyon ve driveline enfeksiyonu görülme arasında geçen ortalama süre 304±309(15-1500) gündü. Alınan sürüntü ve/veya doku kültürlerinde en çok tespit edilen mikroorganizmalar gram pozitif koklar idi. Yedi hastada oral antibiyotik, 25 hastada ise hastaneye yatırılarak sistemik antibiyotik tedavisine gereksinim duyuldu. On üç hastada oral/sistemik antibiyotik tedavisi ile enfeksiyon kontrol altına alırken 15 hastada ise cerrahi olarak debridman yapıldı, üç hastada driveline daha yukarı bir bölgeye taşındı ve bir hastaya kalp nakli gerekti. Hiçbir hastada cerrahi olarak cihazın çıkarılmasını gerektirecek kontrolsüz enfeksiyona rastlanmadı.

Sonuç: Sol ventrikül destek cihazları yüksek oranda driveline enfeksiyonu oranlarına sahiptir; bu çalışmada oran 1. yılda %24,4 olarak bulunmuştur. Oral veya sistemik antibiyotik tedavisi ile ve/veya seçilmiş vakalarda debridman tedavisi ile enfeksiyon kontrol altına alınmış, nadiren driveline kablosunun taşınması ve kalp nakline ihtiyaç duyulmuştur.

Anahtar Kelimeler

• Sol ventrikül destek cihazı,driveline enfeksiyonu,çıkış yeri.

Kaynakça

1. 1. Mozaffarian D, Benjamin EJ, Go AS et al. Heart disease and stroke statistics-2016 update: a report from the American Heart Association. Circulation 2016; 133: 447-54.
2. 2. Genovese EA, Dew MA, Teuteberg JJ et al. Incidence and Patterns of Adverse Event Onset During the First 60 Days After Ventricular Assist Device Implantation. Ann Thorac Surg 2009; 88: 1162–70.
3. 3. Koval CE, Thuita L, Moazami N, Blackstone E. Evolution and impact of drive-line infection in a large cohort of continuous-flow ventricular assist device recipients. J Hear Lung Transplant 2014; 33: 1164–72.
4. 4. Topkara VK, Kondareddy S, Malik F et al. Infectious complications in patients with left ventricular assist device: etiology and outcomes in the continuousflow era. Ann Thorac Surg 2010; 90: 1270-77.
5. 5. Kirklin JK, Pagani FD, Kormos RL et al. Eighth annual INTERMACS report: Special focus on framing the impact of adverse events. J Hear Lung Transplant 2017; 36: 1080–86.
6. 6. Goldstein DJ, Naftel D, Holman W et al. Continuous-flow devices and percutaneous site infections: clinical outcomes. J Heart Lung Transplant 2012; 31: 1151-57.
7. 7. Pagani FD, Miller LW, Russell SD et al. Extended mechanical circulatory support with a continuous-flow rotary left ventricular assist device. J Am Coll Cardiol 2009; 54: 312-21.
8. 8. Gordon RJ, Weinberg AD, Pagani FD et al. Prospective, multicenter study of ventricular assist device infections. Circulation 2013; 127: 691–702.

9. 9. Kilic A. The future of left ventricular assist devices. J Thorac Dis 2015; 7: 2188–93.
10. 10. Hannan MM, Husain S, Mattner F et al. International Society for Heart and Lung Transplantation. Working formulation for the standardization of definitions of infections in patients using ventricular assist devices. J Heart Lung Transpl 2011; 30: 375–84.
11. 11. Pereda D, Conte JV. Left ventricular assist device driveline infections. Cardiol Clin 2011; 29: 515–27.
12. 12. Akhter SA, Badami A, Murray M et al. Hospital readmissions after continuous-flow left ventricular assist device implantation: incidence, causes, and cost analysis. Ann Thorac Surg 2015; 100: 884–89.
13. 13. Aslam S, Dan J, Topik A et al. Decrease in Driveline Infections with Change in Driveline Management Protocol. VAD J 2016; 2: 1–13.
14. 14. Zierer A, Melby SJ, Voeller RK et al. Lateonset driveline infections: the Achilles’ heel of prolonged left ventricular assist device support. Ann Thorac Surg 2007; 84: 515–20.
15. 15. Meszaros K, Fuehrer U, Grogg S et al. Risk factors for sternal wound infection after open heart operations vary according to type of operation. Ann Thorac Surg 2016; 101: 1418–25.
16. 16. Sharma V, Deo SV, Stulak JM et al. Driveline infections in left ventricular assist devices: implications for destination therapy. Ann Thorac Surg 2012; 94: 1381–86.
17. 17. Menon AK, Baranski S-K, Unterkofler J et al. Special Treatment and Wound Care of the Driveline Exit Site after Left Ventricular Assist Device Implantation. Thorac Cardiovasc Surg 2015; 63: 670–74.
18. 18. Cagliostro B, Levin AP, Fried J et al. Continuous-flow left ventricular assist devices and usefulness of a standardized strategy to reduce drive-line infections. J Hear Lung Transplant 2016; 35: 108–114.
19. 19. Zainah H, Karthikeyan A, Buitron P et al. The Efficacy of Acticoat-Silver Dressing in Preventing Left-entricular-Assisted Device Infections. Immunochem Immunopathol 2016; 2: 2–4.
20. 20. Wus L, Manning M, Entwistle III JW, Entwistle JWC. Left ventricular assist device driveline infection and the frequency of dressing change in hospitalized patients. Hear Lung 2015; 44: 225–29.
21. 21. Dean D, Kallel F, Ewald GA et al. Reduction in driveline infection rates: Results from the HeartMate II Multicenter Driveline Silicone Skin Interface (SSI) Registry. J Heart Lung Transplant 2015; 34: 781-89 .
22. 22. Pavlovic NV, Randell T, Madeira T, Hsu S, Zinoviev R, Abshire M. Risk of left ventricular assist device driveline infection: A systematic literature review. Heart Lung 2019; 48: 90-104.
23. 23. Byrd AL, Belkaid Y, Segre JA. The human skin microbiome. Nat Rev 2018; 16: 143– 55.
24. 24. Kusne S, Mooney M, Danziger-Isakov L et al. An ISHLT consensus document for prevention and management strategies for mechanical circulatory support infection. J Hear Lung Transplant 2017; 36: 1137–53.